WILMINGTON, Delaware, Nov 5 (Reuters) - Pfizer ( PFE )

has removed some conditions in its bid for Metsera ( MTSR ) as

it tries to overcome a rival $10 billion bid by Novo Nordisk

for the obesity drug developer, the U.S. drug giant

said in a letter to a Delaware judge on Wednesday.

Pfizer ( PFE ) will ask a Delaware judge at a hearing on Wednesday

to prevent Metsera ( MTSR ) from ending their merger agreement in favor

of Novo's offer. Pfizer ( PFE ) said it removed conditions on direct

sales of stock and public statements by Metsera ( MTSR ).